Morgan Stanley’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,706
| Closed | -$10.7K | – | 7748 |
|
|
2023
Q2 | $10.7K | Buy |
+1,706
| New | +$11.3K | ﹤0.01% | 6792 |
|
|
2023
Q1 | – | Sell |
-6
| Closed | -$20 | – | 7877 |
|
|
2022
Q4 | $20 | Hold |
6
| – | – | ﹤0.01% | 7769 |
|
|
2022
Q3 | $0 | Sell |
6
-1,386
| -100% | -$6.87K | ﹤0.01% | 8000 |
|
|
2022
Q2 | $7K | Hold |
1,392
| – | – | ﹤0.01% | 7340 |
|
|
2022
Q1 | $14K | Sell |
1,392
-4,443
| -76% | -$41.6K | ﹤0.01% | 7294 |
|
|
2021
Q4 | $63K | Buy |
5,835
+3,671
| +170% | +$55K | ﹤0.01% | 6703 |
|
|
2021
Q3 | $50K | Hold |
2,164
| – | – | ﹤0.01% | 6731 |
|
|
2021
Q2 | $84K | Buy |
2,164
+1,282
| +145% | +$55.9K | ﹤0.01% | 6433 |
|
|
2021
Q1 | $37K | Buy |
882
+727
| +469% | +$35.3K | ﹤0.01% | 6497 |
|
|
2020
Q4 | $7K | Sell |
155
-18
| -10% | -$985 | ﹤0.01% | 6727 |
|
|
2020
Q3 | $19K | Sell |
173
-3,474
| -95% | -$470K | ﹤0.01% | 6094 |
|
|
2020
Q2 | $394K | Buy |
3,647
+152
| +4% | +$13.4K | ﹤0.01% | 4718 |
|
|
2020
Q1 | $233K | Buy |
3,495
+1,818
| +108% | +$164K | ﹤0.01% | 4799 |
|
|
2019
Q4 | $140K | Buy |
+1,677
| New | +$113K | ﹤0.01% | 5547 |
|
Morgan Stanley's LMNL Position: Q3 2023 in Review
Morgan Stanley sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q3 2023, closing a stake of 1,706 shares — an estimated $10.7K sold.
Morgan Stanley first reported a position in LMNL in Q4 2019 and held it in 14 quarters. The position peaked at $394K in Q2 2020. 1 fund tracked by Wall St. Rank holds LMNL as of Q3 2023.
- Morgan Stanley reported no remaining Liminal BioSciences Inc. Common Shares position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 1,706 Liminal BioSciences Inc. Common Shares shares in Q3 2023, an estimated $10.7K.
- Morgan Stanley first reported a position in Liminal BioSciences Inc. Common Shares in Q4 2019 and held it in 14 quarters.
- Morgan Stanley's Liminal BioSciences Inc. Common Shares position peaked at $394K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.